Literature DB >> 3978028

Observations on the pharmacokinetics of low dose aminoglutethimide in patients with advanced breast cancer.

R Stuart-Harris, I Bradbrook, P Morrison, I E Smith, H J Rogers.   

Abstract

Serum aminoglutethimide (AG) and N-acetylaminoglutethimide (NAG) concentrations were measured by high pressure liquid chromatography (HPLC) in 24 postmenopausal women with advanced breast cancer receiving increasing doses of oral AG. Patients received 62.5 mg b.d., 125 mg b.d., 250 mg b.d., and 500 mg b.d. of AG alone, and 500 mg b.d. of AG combined with hydrocortisone (HC) 20 mg b.d. Dose was increased at monthly intervals. Each dose increment was accompanied by a significant rise in serum AG and NAG levels (P less than 0.05). The addition of HC to the dose of 500 mg b.d. of AG did not alter serum AG or NAG concentrations significantly. Although serum AG and NAG levels appeared to increase linearly with dose, serum NAG increased significantly more slowly, leading to a fall in the NAG:AG ratio during therapy. The NAG:AG ratio appeared to stabilise only after about 6 months of treatment.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3978028      PMCID: PMC1977148          DOI: 10.1038/bjc.1985.70

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  18 in total

1.  Stereoselective inhibition of aromatase by enantiomers of aminoglutethimide.

Authors:  P E Graves; H A Salhanick
Journal:  Endocrinology       Date:  1979-07       Impact factor: 4.736

2.  Source of estrogen production in postmenopausal women.

Authors:  J M Grodin; P K Siiteri; P C MacDonald
Journal:  J Clin Endocrinol Metab       Date:  1973-02       Impact factor: 5.958

3.  The partial fate of aminoglutethimide in man.

Authors:  J S Douglas; P J Nicholls
Journal:  J Pharm Pharmacol       Date:  1972-12       Impact factor: 3.765

4.  Plasma precursors of estrogen. I. Extent of conversion of plasma delta-4-androstenedione to estrone in normal males and nonpregnant normal, castrate and adrenalectomized females.

Authors:  P C MacDonald; R P Rombaut; P K Siiteri
Journal:  J Clin Endocrinol Metab       Date:  1967-08       Impact factor: 5.958

5.  The features of hepatic enzyme induction with glutethimide in man.

Authors:  L Jackson; M Homeida; C J Roberts
Journal:  Br J Clin Pharmacol       Date:  1978-12       Impact factor: 4.335

6.  Serum aminoglutethimide levels: studies of serum half-life, clearance, and patient compliance.

Authors:  F T Murray; S Santner; E Samojlik; R J Santen
Journal:  J Clin Pharmacol       Date:  1979 Nov-Dec       Impact factor: 3.126

7.  Aminoglutethimide in the treatment of advanced postmenopausal breast cancer.

Authors:  A L Harris; T J Powles; I E Smith
Journal:  Cancer Res       Date:  1982-08       Impact factor: 12.701

8.  Overview of recent development of aromatase inhibitors.

Authors:  A M Brodie
Journal:  Cancer Res       Date:  1982-08       Impact factor: 12.701

9.  Aminoglutethimide in treatment of metastatic breast carcinoma.

Authors:  I E Smith; B M Fitzharris; J A McKinna; D R Fahmy; A G Nash; A M Neville; J C Gazet; H T Ford; T J Powles
Journal:  Lancet       Date:  1978-09-23       Impact factor: 79.321

10.  Aminoglutethimide bioavailability, pharmacokinetics, and binding to blood constituents.

Authors:  T A Thompson; J D Vermeulen; W E Wagner; A R Le Sher
Journal:  J Pharm Sci       Date:  1981-09       Impact factor: 3.534

View more
  6 in total

Review 1.  Clinical pharmacokinetics of endocrine agents used in advanced breast cancer.

Authors:  P E Lønning; E A Lien; S Lundgren; S Kvinnsland
Journal:  Clin Pharmacokinet       Date:  1992-05       Impact factor: 6.447

2.  Clinical pharmacology of aminoglutethimide in patients with metastatic breast cancer.

Authors:  A A Miller; B E Miller; K Höffken; C G Schmidt
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

3.  Single-dose and steady-state pharmacokinetics of aminoglutethimide.

Authors:  P E Lønning; J S Schanche; S Kvinnsland; P M Ueland
Journal:  Clin Pharmacokinet       Date:  1985 Jul-Aug       Impact factor: 6.447

Review 4.  Mechanisms of action of aminoglutethimide as endocrine therapy of breast cancer.

Authors:  P E Lønning; S Kvinnsland
Journal:  Drugs       Date:  1988-06       Impact factor: 9.546

5.  Aminoglutethimide in advanced breast cancer: plasma levels and clinical results after low and high doses.

Authors:  E Strocchi; C M Camaggi; A Martoni; R Cellerino; S Miseria; P Malacarne; M Indelli; M Balli; G Bonciarelli; G Ambroso
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

6.  The influence of CGS 16949A on peripheral aromatisation in breast cancer patients.

Authors:  P E Lønning; S Jacobs; A Jones; B Haynes; T Powles; M Dowsett
Journal:  Br J Cancer       Date:  1991-05       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.